test

Lieping Chen MD, PhD

United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology); Director, Cancer Immunology Program at Yale Cancer Center

Departments & Organizations

Yale Combined Program in the Biological and Biomedical Sciences (BBS): Immunology

Cancer Immunology

Immunobiology: HTI

Dermatology


Research Interests

Lymphocyte activation and tolerance; Costimulation and coinhibition; Tumor site immune modulation; Immunotherapy of advanced human cancer; Immunotherapy of advanced autoimmune diseases more...


Education

  • M.D., Fujian Medical College, 1982
  • M.S., Beijing Union Medical College, Beijing, China, 1986
  • Ph.D., Drexel University, 1989

Selected Publications

  • Kohrt HE, Colevas AD, Houot R, Weiskopt K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J and Levy R. Targeting CD137 enhances efficacy of cetuximab. Journal of Clinical Investigation 124(6):2668-2682, 2014
  • Flies DB, Han X, Higuchi T, Zheng LH, Sun JW, Ye JJ and Chen L. Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity. Journal of Clinical Investigation 124(5):1966-1975, 2014
  • Zhu Y, Yao S, Iliopoulou B, Han X, Augustine M, Xu H, Phennicie RT, Flies SJ, Broadwater M, Ruff W, Taube JM, Zheng LH, Luo L, Zhu G, Chen J and Chen L. B7-H5 costimulates human T cells via CD28H. Nature Communications 4:2043, 2013

more...

collapsible-single-column-one-thumbnailphotobooksupi=13515226/WCF/News.svc/

Latest News

3
more...

Edit Profile